PET Image in PAH Patients
Utilizing 18F-fluoroglutamine PET Imaging in Patients With Pulmonary Arterial Hypertension
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years to 75 Years
- Sex
- All sexes
- Healthy volunteers
- Accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
- Procedures mentioned: MRI scans, CT scans, PET scans
Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.
Show the study's own words
- "Efforts have been made to develop such imaging capabilities through platform development of echocardiography, cardiac MRI, chest computed tomography (CT), and positron emission tomography (PET), among others."
- "Study visit: The study visit will take around 3-4 hours, the duration of PET scan will be around 90 minutes."
- "All PET scans will be performed for a single bed position on a Siemens Biograph mCT Flow."
- "A low dose helical CT scan will be performed during a \~15 sec inspiratory breath hold and used for CT-based attenuation correction of PET emission data and as an anatomical reference for image analyses."
- "Follow-up Procedures: A follow-up telephone call will be made to subjects by the research team approximately 1 to 7 days after the PET/CT scan to inquire about any adverse events the participant may have encountered related to the scans."
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
Pulmonary arterial hypertension (PAH) is mortal disease affecting the blood vessels of the lung. Despite its morbid prognosis, PAH is often misdiagnosed or ignored, with an average time of 44 months between onset of symptoms to diagnosis and substantial progression of disease severity. Therefore, a pressing need exists to develop non-invasive diagnostic imaging tools, particularly that can detect early disease stages. Efforts have been made to develop such imaging capabilities through platform development of echocardiography, cardiac MRI, chest computed tomography (CT), and positron emission tomography (PET), among others. While some have demonstrated promise, few have shown a precise ability to offer disease quantifications of the diseased lung and vasculature itself, to detect early stages of disease, and to reflect alterations of the lung, vasculature, and right ventricle that reflect the molecular origins of this disease. \[F-18\]FGln has been previously utilized in oncology studies as a non-invasive in vivo imaging biomarker of tumor glutamine flux and metabolism. Our preliminary in vivo pre-clinical rodent studies demonstrated that \[F-18\]FGln demonstrated increased uptake in diseased pulmonary vessels and the right ventricle in a rodent model of PAH. The proposed research study will provide preliminary evidence of the potential to utilize \[F-18\]FGln as a non-invasive imaging biomarker of glutamine flux and metabolism across a range of PAH subjects.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria: Cases: 1. Age between 18-75 years old 2. Confirmed diagnosis of SSc-PAH / SSc-eiPAH/IPAH/ by right heart catheterization. And Scleroderma with no PAH confirmand by echo. Controls: 1. Age between 18-75 years old 2. Individuals who are at low risk for current or future cardiovascular or pulmonary symptoms or diseases Exclusion Criteria: Cases: 1. Smoking 2. Pregnant/ breast feeding women 3. Children under 18 4. Inability to read and understand the informed consent 5. History of CT contrast allergy 6. Inability to lie down for long period of time 7. Having claustrophobic 8. History of radiation exposure at workplace 9. Consuming more than 2-3 alcoholic drinks a week 10. Working previously in any of the following "cool miner, painter, iron miner, Mill worker, asbestos, insulation/heat resistance materials, sand" 11. Any medical conditions involving the heart or lungs that would make participation in the study unsafe in the opinion of the PI. Controls: 1. Smoking 2. Pregnant/ breast feeding women 3. Children under 18 4. Inability to read and understand the informed consent 5. History of CT contrast allergy. 6. Inability to lie down for long period of time 7. Having claustrophobic 8. History of radiation exposure at workplace 9. Consuming more than 2-3 alcoholic drinks a week 10. Working previously in any of the following "coal miner, painter, iron miner, Mill worker, asbestos, insulation/heat resistance materials, sand" 11. Any medical conditions involving the heart or lungs or that would make participation in the study unsafe in the opinion of the PI. 12. Family history of Pulmonary Hypertension or Scleroderma
Study sites (1)
PA
- Montefiore Hospital Clinical and Translational Research Center · Pittsburgh, PA 15213Yassmin Al Aaraj · Study contactMore trials in Pittsburgh